Wolverine Trading
NAUT icon

Wolverine Trading’s Nautilus Biotechnolgy NAUT Stock Holding History

Wolverine Trading’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-32,326
Closed -$85K – 4687
2023
Q1 		$85K Buy
+32,326
New +$67.8K ﹤0.01% 3703

Other funds holding NAUT

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CM
Cercano Management Bellevue, Washington $750M AUM 25.77% 1-Year Est. Return
MVG
Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CFM
Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $4.42B AUM 22.6% 1-Year Est. Return
AI
ArchPoint Investors Coral Gables, Florida $473M AUM 49.24% 1-Year Est. Return
AEPLI
AH Equity Partners LSV II Menlo Park, California $95.6M AUM 8.86% 1-Year Est. Return

Wolverine Trading's NAUT Position: Q2 2023 in Review

Wolverine Trading sold out of Nautilus Biotechnolgy (NAUT) in Q2 2023, closing a stake of 32,326 shares — an estimated $85K sold.

Wolverine Trading first reported a position in NAUT in Q1 2023 and held it in 1 quarter. The position peaked at $85K in Q1 2023. 75 funds tracked by Wall St. Rank hold NAUT as of Q2 2023.

  • Wolverine Trading reported no remaining Nautilus Biotechnolgy position as of Q2 2023 after selling out during the quarter.
  • Wolverine Trading sold 32,326 Nautilus Biotechnolgy shares in Q2 2023, an estimated $85K.
  • Wolverine Trading first reported a position in Nautilus Biotechnolgy in Q1 2023 and held it in 1 quarter.
  • Wolverine Trading's Nautilus Biotechnolgy position peaked at $85K in Q1 2023.
  • 75 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q2 2023.

Based on Wolverine Trading's 13F filing for Q2 2023, filed 23 Aug 2023.